Division of Hematology Research

The Division of Hematology at CHOP is committed to several research initiatives, each with a singular goal: Advance the treatment of childhood blood diseases.

We have researchers covering the full spectrum of investigation, from basic research to translational and clinical studies that are advancing patient therapies. Here are some examples of CHOP's latest hematology research:

Sickle Cell Center

IMAGE: Colket Building
The Colket research building, home to the Center for Cellular and Molecular Therapeutics.

Recent and ongoing studies in the Sickle Cell Center are funded by the National Institutes of Health (NIH), the NIH-funded Comprehensive Sickle Cell Center Program, non-governmental funding agencies, corporations, and community organizations and individuals. We are one of 10 Comprehensive Sickle Cell centers in the nation funded on a competitive basis by the NIH's National Heart, Lung and Blood Institute. Our studies include:

Center for Cellular and Molecular Therapeutics

The Center for Cellular and Molecular Therapeutics facilitates rapid translation of pre-clinical discoveries into clinical application. One of few such programs based at a pediatric institution, the center collaborates with other major programs to pursue new therapies for inherited and acquired disorders. Katherine A. High, MD, is the director of the Center for Cellular and Molecular Therapeutics at CHOP. Current research includes:

Pediatric & Adult Comprehensive Bone Marrow Failure Center

CHOP's Pediatric & Adult Comprehensive Bone Marrow Failure Center launched in 2010, representing a major advance in bone marrow diseases. Bone marrow failure, which can be inherited or acquired, is the inability of the bone marrow to produce sufficient circulating blood cells. Monica Bessler, MD, PhD, is founder and director of the Center.

The Normal and Malignant Hematopoiesis Research Affinity Group

The Normal and Malignant Hematopoeisis Research Affinity Group aims to address problems in gene and protein networks that signal blood cell maturation from primitive bone marrow progenitor cells, as well as networks that regulate the balance of cell growth and cell death. These networks are relevant to hematopoiesis, and understanding more about how they regulate the development of specific blood cell elements in normal and diseased states will allow for development of targeted prevention and more effective treatments for disordered hematopoiesis, leukemia and lymphoproliferative diseases in children.

  • Print
  • Share

Contact Us